{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-018694","form_type":"8-K","ticker":"KALA","cik":"0001479419","company_name":"KALA BIO, Inc.","filed_at":"2023-11-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.200045+00:00","generated_at":"2026-06-08T04:55:55.462064+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"KALA BIO Q3 2023 net loss $8.7M; CHASE Phase 2b enrollment ongoing, topline data 2H 2024","bullets":["Net loss $8.7M ($3.41 per share) vs net income $29.1M in Q3 2022 due to prior year gain on sale of commercial business.","Cash and equivalents $56.1M at Sep 30, 2023; together with CIRM award funds expected to fuel operations into Q2 2025.","CHASE Phase 2b trial of KPI-012 for PCED actively enrolling; topline safety and efficacy data targeted for 2H 2024.","R&D expenses $5.6M (up $0.2M YoY); SG&A expenses $5.0M (down $4.5M YoY) after sale of commercial portfolio.","No product revenues in Q3 2023; preclinical evaluation of KPI-014 for inherited retinal degenerative diseases initiated."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-018694","json":"https://secwatch.observer/filing/0001558370-23-018694.json","markdown":"https://secwatch.observer/filing/0001558370-23-018694.md","text":"https://secwatch.observer/filing/0001558370-23-018694.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/0001558370-23-018694-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/kala-20231113x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T04:55:55.462064+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"8da3e54c9e75032b852ad9672465a4dee87133ad","claim":"KALA BIO, Inc. reported financial results for the third quarter ended September 30, 2023.","evidence_excerpt":"On November 13, 2023, KALA BIO, Inc. announced its financial results for the quarter ended September 30, 2023 and provided a general business update. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1479419/000155837023018694/0001558370-23-018694-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}